MÇMustafa Çolak

Mustafa Çolak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mustafa Çolak has a total of 101 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Decoding the night: a machine learning approach to diagnose and predict the severity of obstructive sleep apnea through clinical parameters

    by Neslihan Özçelik, Emre Bendeş, Ali Erdem Özçelik, Elvan Şentürk Topaloğlu, Songül Özyurt, Mehmet Karadağ, Özge Aydın Güçlü, Merve Nur Yıldız, Hadice Selimoğlu Şen, Nur Aleyna Yetkin, et al.

  • Open Access

    Can the Prognostic Nutritional Index Be a Predictor of Acute Exacerbation of Idiopathic Pulmonary Fibrosis?

    by Mustafa Çolak, Hikmet Çoban

    Background/Objectives: Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease that can be accompanied by acute exacerbations. To investigate the predictive value of the prognostic nutritional index (PNI) for acute exacerbation in patients with IPF. Methods: Ninety-seven patients diagnosed with IPF between 03/2019 and 03/2024 were retrospectively evaluated. Patients were divided into two groups according to exacerbation status (acute exacerbation group n = 28, non-acute exacerbation group n = 69). PNI values were calculated. The predictive value of the PNI for acute exacerbation was analyzed between groups. ROC analysis and multivariable logistic regression were performed. Results: Of the 97 patients, 78 (80.4%) were male with a mean age of 71.31 ± 6.61 years. The mean disease duration was 24.77 ± 15.69 months. During follow-up, 28 patients (28.9%) had acute exacerbations. Lymphocyte count and albumin level were significantly lower in the acute exacerbation group (p < 0.001, p < 0.001, respectively). The mean PNI value was significantly lower in the acute exacerbation group (46.62 ± 6.28) compared to the non-acute exacerbation group (52.04 ± 5.46) (p < 0.001). In addition, FEV1%, FVC%, and DLCO% values were significantly lower in the acute exacerbation group (p < 0.001, p < 0.001, p < 0.001, respectively). In ROC analysis, the cut-off value of PNI ≤ 48.50 had a sensitivity of 64.29% and specificity of 78.26% (AUC:0.744, p < 0.001). In multivariable logistic regression analysis, the PNI (OR = 0.857, p = 0.007) and FVC% (OR = 0.949, p = 0.008) were independent predictors of acute exacerbation. Conclusions: The PNI may serve as a negative biomarker for predicting acute exacerbation risk in IPF patients. This simple, cost-effective parameter could be useful in risk assessment.

  • Association Between Obstructive Sleep Apnea Severity and Cardiometabolic Index in the Context of Cardiovascular Risk

    by Mustafa Colak, Hikmet Coban, Merve Yumrukuz Senel, Gulcin Yilmaz, Nurhan Sarioglu, Fuat Erel

    Amaç: Çalışmamız, Kardiyometabolik İndeks (KMİ) ile Obstrüktif Uyku Apne (OUA) arasındaki ilişkiyi değerlendirmeyi ve kardiyovasküler risk değerlendirmesindeki potansiyel klinik önemini araştırmayı amaçlamaktadır. Gereç ve Yöntemler: Ocak 2022 ile Temmuz 2023 tarihleri arasında uyku apnesi ön tanısıyla polisomnografi (PSG) uygulanan toplam 158 hasta çalışmaya dahil edildi. Demografik veriler, antropometrik ölçümler, eşlik eden hastalıklar, biyokimyasal parametreler ve KMİ değerleri analiz edildi. Bulgular: Çalışmaya 112'si erkek (%70,9) olmak üzere toplam 158 hasta alındı. Kardiyometabolik indeks değerlerinin, OUA şiddeti arttıkça anlamlı derecede yükseldiği saptandı (p=0,03). Apne-hipopne indeksi ile KMİ arasında düşük düzeyde pozitif korelasyon bulundu (r=0,21, p<0,001, %95 GA: 0,001-0,020). Ağır OUA olan hastalar ile basit horlama olan hastalar arasında KMİ değerlerinde 0,88 birimlik mutlak fark tespit edildi. Kardiyometabolik indeks, kardiyovasküler hastalığı olan hastalarda daha yüksek saptanmasına rağmen, aralarında anlamlı derecede fark bulunmadı (p=0,385). Sonuç: Obstrüktif uyku apnesi şiddeti ile KMİ arasında anlamlı pozitif bir ilişki saptadık. Kardiyometabolik indeksin, uyku apnesi olan hastalarda kardiyovasküler riskle ilişkili olumsuz kardiyometabolik profili yansıtan basit ve pratik bir belirteç olarak kullanılabileceğini öne sürüyoruz.

  • Open Access

    Hepcidin as a Biomarker of Response to Antifibrotic Therapy in Idiopathic Pulmonary Fibrosis

    by Gulcin Yilmaz Gunes, Hikmet Çoban, Fuat Erel, Merve Akış Yılmaz, Nurhan Sarioglu, Mustafa Colak, Merve Yumrukuz Senel

    Background/Objectives: Idiopathic pulmonary fibrosis (IPF) may progress despite antifibrotic therapy, highlighting the need for biomarkers of early treatment-associated biological changes. This study aimed to assess the potential role of hepcidin in monitoring treatment response by evaluating pre- and post-treatment serum hepcidin levels in patients with IPF receiving antifibrotic therapy. Methods: This prospective observational cohort study included 38 clinically stable patients diagnosed with IPF according to the 2022 American Thoracic Society/European Respiratory Society (ATS/ERS)criteria between January and July 2025. Serum hepcidin was measured by ELISA at antifibrotic therapy initiation and month 3. Demographic data, pulmonary function tests, diffusing capacity for carbon monoxide (DLCO), and 6 min walk test results were recorded. Analyses were performed using SPSS 25.0. Results: Mean serum hepcidin decreased from 33.00 ± 16.74 to 24.41 ± 12.42 ng/mL (p < 0.001), with reductions observed in 30 of 38 patients (78.9%). Mean forced vital capacity (FVC) increased from 73.83 ± 18.10% predicted to 77.74 ± 15.70% predicted (p < 0.001). Median DLCO increased from 68.50 (51.00–80.50)% predicted to 72.50 (60.00–83.75)% predicted (p < 0.001). Six-minute walk distance did not change significantly (p = 0.078), nor did hemoglobin, C-reactive protein, or erythrocyte sedimentation rate. The change in hepcidin did not differ between the pirfenidone and nintedanib groups (p = 0.817). Although FVC and DLCO increased over three months, these short-term functional changes should be interpreted cautiously, as test familiarization, measurement variability, and regression to the mean cannot be excluded; therefore, they should not be considered evidence of fibrosis reversal or a direct treatment effect. Conclusions: Our study provides the first real-world data demonstrating a significant decrease in serum hepcidin following antifibrotic treatment in patients with IPF. These findings suggest that serum hepcidin may have potential clinical utility as a biomarker for assessing response to antifibrotic therapy in IPF.

  • Open Access

    Could Hepcidin Be a Phenotype-Related Biomarker in Patients with Stable Bronchiectasis?

    by Gulcin Yilmaz Gunes, Hikmet Çoban, Fuat Erel, Merve Akış Yılmaz, Nurhan Sarioglu, Mustafa Colak, Merve Yumrukuz Senel, Ayşe Dilvin Mansır Elmalı

    Hepcidin centrally regulates iron homeostasis and responds to inflammation, iron status, hypoxia, and erythropoietic signaling, yet circulating hepcidin in stable bronchiectasis is poorly characterized. We compared serum hepcidin between 61 patients with stable bronchiectasis and 39 controls without bronchiectasis and assessed associations with anemia, iron metabolism, systemic inflammation, severity, and phenotype. Hepcidin was lower in bronchiectasis (20.34 ± 7.85 vs. 28.34 ± 9.82 ng/mL; median, 20.31 [15.07–25.35] vs. 25.03 [21.00–34.66] ng/mL; p < 0.001). It showed no significant associations with anemia status or hematologic, iron metabolism, erythropoietic, or inflammatory indices. Exploratory analyses identified phenotype differences (p = 0.002); levels were lowest in chronic obstructive pulmonary disease–bronchiectasis (15.98 ± 6.52 ng/mL), compared with bronchiectasis alone (21.57 ± 6.71) and asthma–bronchiectasis (24.81 ± 9.00). Low hepcidin discriminated bronchiectasis from controls (AUC = 0.729; 95% bootstrap CI: 0.628–0.822); the ≤20.85 ng/mL cutoff yielded 59.0% sensitivity and 79.5% specificity. To our knowledge, this is the first human case–control evidence of reduced circulating hepcidin in stable bronchiectasis. The absence of significant associations with systemic inflammation or anemia/iron status, alongside phenotype differences, suggests that hepcidin may be a candidate biomarker of biological heterogeneity in bronchiectasis not reflected by routine markers.

  • Open Access

    The Effect on Vitamin D Levels and VDR Gene Polymorphism on Clinical Outcomes in Asthma

    by Gülden Deniz Aksu, Nurhan Sarıoğlu, Mustafa Çolak, Ayla Solmaz Avcıkurt, Hikmet Çoban, Adnan Adil Hişmioğulları, Fuat Erel

    Objective: This study aimed to investigate the relationship between vitamin D receptor gene polymorphism and vitamin D levels with asthma severity, control level and exacerbation status in asthmatic patients. Subjects and Methods: Over a six-month period, 162 patients diagnosed with asthma and 85 healthy volunteers were prospectively evaluated. Blood samples were analyzed for Vitamin D receptor gene polymorphism by PCR and periostin by ELISA. Results: Among the study participants, 163 were females and 84 were males. The median value of Vitamin D in the patient group was significantly lower at 13.95 (3.5-33) compared to 17 (6.1-39.9) in the control group (p = 0.003). A significant positive correlation was found between Vitamin D and Asthma Control Test (ACT), eosinophil count, Peak Expiratory Flow (PEF, %) (r:0.18 to 0.25 p < 0.05). When VDR gene polymorphism Fok1 and Apa1 alleles in the patient and control groups were examined, they were found to be similar (p > 0.05). However, when VDR gene polymorphism genotypes were analyzed in terms of vitamin D levels, no significant difference was found between Apa1 genotypes (CC, CT, TT). Regression analysis of variables which are considered to influence Vitamin D levels showed that gender and PEF are independent determinants. Conclusions: In our study, a significant relationship was found between Vitamin D levels and asthma severity, asthma control level, and respiratory functions. However, no significant effect of VDR gene polymorphism was detected on the vitamin D levels and asthma.

  • Open Access

    The Relationship Between Hepcidin and the Severity of Obstructive Sleep Apnea Syndrome and Obesity

    by Hikmet Coban, Emine Ayan, Mustafa Colak, Nurhan Sarioglu, Gulcin Yilmaz Gunes, Fuat Erel, Merve Yumrukuz Senel, Merve Akış Yılmaz

    The effects of chronic intermittent hypoxia associated with obstructive sleep apnea (OSA) on iron metabolism remain incompletely understood. This study aimed to evaluate whether serum hepcidin levels are associated with OSA severity independently of obesity and systemic inflammation. A total of 136 patients who underwent polysomnography for suspected OSA between April and December 2025 were included in the study. Participants were classified into control and OSA groups according to the Apnea–Hypopnea Index (AHI), and the OSA group was further categorized as mild, moderate, or severe. Demographic and anthropometric characteristics and Epworth Sleepiness Scale scores were recorded. Serum hepcidin levels were measured using an ELISA method and compared between groups, and their associations with clinical and polysomnographic parameters were analyzed. Serum hepcidin levels were significantly higher in patients with OSA than in the control group (48.83 ± 11.92 vs. 41.53 ± 12.43 ng/mL; p < 0.001) and increased progressively with disease severity. Hepcidin levels were not significantly correlated with conventional iron parameters but showed a strong positive association with the Oxygen Desaturation Index (ODI). In multivariable regression analysis, the positive relationship between AHI and serum hepcidin levels remained significant after adjustment for body mass index and C-reactive protein levels (p < 0.001). These findings suggest that elevated serum hepcidin levels in OSA are linked to hypoxic stress independently of obesity and systemic inflammation, indicating that hepcidin may represent a potential biomarker reflecting disease severity in OSA.


  • Open Access

    Electrical Cardiometry as a Novel Tool for Assessing Systemic Vascular Resistance and Cardiac Function in Obstructive Sleep Apnea

    by Seda Elcim Yildirim, Nurhan Sarioglu, Mustafa Colak, Ibrahim Tanriogen, Tarik Yildirim, Tuncay Kiris, Eyüp Avci

    Background: Obstructive sleep apnea syndrome (OSAS) is associated with sympathetic overactivity, intermittent hypoxia, and increased vascular resistance, leading to cardiovascular morbidity. Electrical cardiometry (EC) is a novel, non-invasive technology that continuously measures hemodynamic parameters such as systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), cardiac output (CO), and cardiac index (CI). The aim of this study was to compare SVR and SVRI values, measured by EC, between patients with OSAS and age- and sex-matched healthy controls. Methods: In this retrospective case–control study, 70 participants were enrolled, including 33 patients with polysomnography-confirmed OSAS and 37 healthy controls matched for age and sex. All participants underwent standard EC measurement (ICON® Cardiotronics, Osypka Medical, GmbH, Berlin, Germany) under resting, supine conditions. Hemodynamic parameters such as SVR, SVRI, and CI were compared between groups. Results: EC revealed significantly higher SVR (1498.7 ± 335.6 vs. 1260.1 ± 251.5 dyn·s·cm−5, p = 0.013) and SVRI (2969.4 ± 749.1 vs. 2347.4 ± 481.0 dyn·s·cm−5·m2, p < 0.001) in patients with OSAS compared with controls, while CI was significantly lower in the OSAS group (2.6 ± 0.5 vs. 3.2 ± 0.8 L/min/m2, p < 0.001), indicating increased vascular load and reduced cardiac performance. Conclusions: This study is the first to apply EC in OSAS. EC-derived parameters, particularly SVRI and CI, effectively differentiated OSAS patients from healthy subjects, reflecting increased vascular afterload and reduced cardiac performance. These findings suggest that EC is a feasible, non-invasive tool for assessing hemodynamic alterations in OSAS and may have potential for bedside monitoring and future risk stratification studies.


  • Open Access

    Artificial intelligence chatbots and idiopathic pulmonary fibrosis: are they ready to inform patients?

    by Merve Yumrukuz Şenel, Emine Ayan, Mustafa Çolak, Hikmet Çoban, Fuat Erel, Nurhan Sarıoğlu

    SUMMARY OBJECTIVE: The aim of this study was to determine the quality, reliability, and readability of the responses provided by artificial intelligence chatbots about idiopathic pulmonary fibrosis. METHODS: The clinically relevant questions about idiopathic pulmonary fibrosis diagnosis, treatment, prognosis, and lifestyle management were submitted to four widely used artificial intelligence chatbots, including ChatGPT, Perplexity, Gemini, and Copilot. Responses were assessed by five clinicians based on readability, understandability, quality, and content reliability using standardized tools. RESULTS: The overall readability of chatbot-generated responses was low, corresponding to high educational requirements. Understandability ranged from moderate to good, whereas actionability remained moderate. Gemini produced the most readable and understandable outputs. Journal of the American Medical Association and Likert scores indicated limited source transparency but good guideline concordance. DISCERN analysis for the treatment question showed significant variation (p=0.003), with Perplexity achieving the highest total score. CONCLUSION: Although artificial intelligence chatbots offer rapid and accessible information, their readability and source reliability remain limited. These findings highlight the necessity of expert supervision and further model improvement before artificial intelligence chatbots can be safely integrated into patient education.


  • Open Access

    Can Pirfenidone and Nintedanib Be Alternative Treatment Options for Radiation Pneumonitis?

    by Hikmet Coban, Mustafa Colak, Merve Yumrukuz Şenel, Muzaffer Gunes, Nurhan Sarioglu, Fuat Erel